Daiichi starts late-stage study of flu drug laninamivir

11/5/2009 | Reuters

Daiichi Sankyo commenced a Phase III trial of laninamivir, its inhaled drug candidate for H1N1 and bird flu infections. Daiichi plans to submit the drug for approval by March and launch it a year later.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC